On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors
Authors:
- Philip J. MeasePMPhilip J. Mease
- Jessica A. WalshJWJessica A. Walsh
- Timothy P. FitzgeraldTFTimothy P. Fitzgerald
- Soumya D. ChakravartySCSoumya D. Chakravarty
- Elizabeth AdamsonEAElizabeth Adamson
- Bruno EmondBEBruno Emond
- Carmine RossiCRCarmine Rossi
- Samuel SchwartzbeinSSSamuel Schwartzbein
- Kana YokojiKYKana Yokoji
- Yuxi WangYWYuxi Wang
- Patrick LefebvrePLPatrick Lefebvre
- Dominic PilonDPDominic Pilon
Open Access
- 14 November 2025
- journal article
- research article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 13 (1) , 115-134
Abstract
Introduction There is limited prior literature comparing long-term treatment persistence between guselkumab and subcutaneous (SC) tumor necrosis factor inhibitors (TNFi) in biologic-naïve and biologic-experienced patients with active psoriatic arthritis (PsA). This study compared on-label persistence through 24 months between patients with active PsA newly initiating guselkumab or SC TNFi. Methods IQVIA PharMetrics® Plus database was used to identify adults with active PsA initiating guselkumab or an SC TNFi (adalimumab or biosimilar, certolizumab pegol, etanercept or biosimilar, SC golimumab) between 07/14/2020 and 12/31/2022 (index date: first treatment claim for one of these medications). Patients were further stratified as biologic-naïve (no pre-index biologic disease-modifying antirheumatic drug [bDMARD] claim) or biologic-experienced (≥ 1 pre-index bDMARD claim). The guselkumab and SC TNFi cohorts were balanced using overlap propensity score weighting. Treatment persistence with on-label therapy (absence of dose modification or therapy exposure gap of twice the duration between consecutive administrations, i.e., 112 days for guselkumab or 56 days for SC TNFi) was estimated using weighted Kaplan–Meier analysis through 24 months. On-label persistence rates were compared between cohorts using weighted Cox proportional hazards models. Results In the guselkumab cohort (N = 804), 361 (44.9%) were biologic-naïve and 443 (55.1%) were biologic-experienced; in the SC TNFi cohort (N = 2490), 2171 (87.2%) were biologic-naïve and 319 (12.8%) were biologic-experienced. At 24 months post index, on-label persistence rates were 45.5% (guselkumab) versus 28.5% (SC TNFi; P < 0.001). Patients initiating guselkumab were 2.24 times more likely to be persistent with on-label therapy through 24 months than patients initiating an SC TNFi (hazard ratio [95% confidence interval] 2.24 [1.90, 2.64]; P < 0.001). Results were consistent among biologic-naïve (2.36 [1.88, 2.98]; P < 0.001) and biologic-experienced patients (1.86 [1.46, 2.37]; P < 0.001). Conclusion Patients with active PsA initiating guselkumab were significantly (approximately two times) more likely to remain persistent with on-label therapy through 24 months versus SC TNFi, overall and among biologic-naïve and biologic-experienced subgroups.Keywords
Funding Information
- Johnson and Johnson
This publication has 36 references indexed in Scilit:
- Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryRheumatology and Therapy, 2023
- Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USADermatology and Therapy, 2023
- Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 StudyACR Open Rheumatology, 2023
- Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With PsoriasisJAMA Dermatology, 2022
- Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance DatabaseJAMA Dermatology, 2022
- Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic ArthritisArthritis & Rheumatology, 2022
- The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population‐Based StudyArthritis & Rheumatology, 2021
- Overlap WeightingJAMA, 2020
- 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic ArthritisArthritis & Rheumatology, 2018
- Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United StatesJAMA Dermatology, 2013